leisure time -WSS

leisure time

author：focus 2025-10-02 21:05:52 - browse：883

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Novel spinal cord stimulator treats paralysis without surgery

focus

WSS

Sepsis can kill a child within hours. Here's how hospitals are fighting back

The effects of a landmark ruling on DNA ownership are becoming clearer

JPM: CVS says Medicare Advantage patients are impacting profits

How a small hospital in rural Puerto Rico survived Hurricane Maria

The effects of a landmark ruling on DNA ownership are becoming clearer

Goldman Sachs launches $650M fund for life science investments

focus

leisure time

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Sports medicine is finally prioritizing gender equality

Welsh Carson private equity firm escapes from FTC antitrust case

Duchenne breakthrough therapy leaves behind pioneering families

Welsh Carson private equity firm escapes from FTC antitrust case

How to save PrEP access — and even expand it

Warren pushes Witty on UnitedHealth's control over physicians

Novavax promises a turnaround & Lilly roils the obesity market

New weight loss drugs work. But how can they best be used?

focus

Ahead of JPM, here's who's profiting most in health care

Brain technologies pose threats that are all too real, experts warn

The effects of a landmark ruling on DNA ownership are becoming clearer

U.K. sequencing study surfaces new findings about tumor DNA

Antibiotic resistance and the global rise in human conflict

Most antidepressants don't work on kids, teens, study finds

focus

focus

leisure time

hotspot